Update in Pharmacotherapy for Hypertension - 1 Contact Hour
In 2014, a much-anticipated update to the 2003 JNC guidelines for hypertensive management was released. The 2014 update was met with mixed responses in the medical community and was further complicated by the results of the SPRINT trial in 2015. To address areas of controversy, a multi-organization consensus guideline was released in 2017. After an 11-year period of consistency, the plethora of guidelines releases has resulted in confusion in the clinical community.
This activity will provide a clear overview of updated recommendations with a focus on drug therapy. It is relevant for new and experienced pharmacists, pharmacy technicians, nurses, and advanced practice providers.
Pharmacist Learning Objectives
At the conclusion of this continuing education activity, the participant will be able to:
- Recognize updates related to the classification of hypertension and prehypertension
- Identify patient-specific factors that the guide selection of agents for hypertension
- Determine strategies for addressing non-adherence to anti-hypertensive therapy
AchieveCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. AchieveCE is also accredited by the Florida Board of Pharmacy (provider no. 50-20641).
AchieveCE is an approved provider of nursing continuing professional development by the Georgia Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
AchieveCE is also an approved provider by various state boards.
Jineane Venci, PharmD, BCACP received her Doctorate of Pharmacy from the University at Buffalo School of Pharmacy and Pharmaceutical Sciences and a Master of Science in Clinical Investigation from the University of Rochester. She completed a PGY1 residency and is board certified in ambulatory pharmacotherapy.
Financial Support Disclosure
This activity was developed by AchieveCE free of any commercial support. Jineane Venci, PharmD, BCACP, faculty for this educational event, has no relevant financial relationship(s) with ineligible companies to disclose.
Jaimini Patel, RPh, and Pete Kreckel, RPh, planners for this educational event, also have no relevant financial relationship(s) with ineligible companies to disclose.
Should you be interested in taking this course offline, you may download this Activity Handout by clicking this link
. Please return to this course page to take the Assessment Questions required for credit. A passing grade of 70 or higher and completion of an online activity evaluation are required to earn credit. Please click on the Complete and Continue buttons at the bottom of every page to track your progress.
- Knowledge Check
- Update in Pharmacotherapy for Hypertension
- About the Faculty
- Faculty Disclosure
- Learning Objectives
- General Principles
- Part 1: Case 1
- 2017 Classifications of Blood Pressure
- Part 2: Case 1
- Treatment & Monitoring
- Goal Blood Pressure
- Part 3: Case 1
- Thiazide Diuretics
- Thiazides - Adverse Effects
- ACEs/ARBS - Adverse Effects
- Dihydropyridine Calcium Channel Blockers
- Dihydropyridine CCBs - Adverse Effects
- Part 4: Case 1
- Assessment Question
- Barrier to Adherence
- Mineralocorticoid Antagonists
- Part 1: Beta Blockers
- Beta Blockers - Adverse Effects
- Part 2: Beta Blockers
- Non-Dihydropyridine Calcium Channel Blockers
- Assessment Question
- Third Line Therapies
- Central Alpha-2 Agonists
- Alpha-1 Antagonists
- Drug Induced Hypertension
- Key Takeaways
- Course Evaluation